Home/Kallyope/Jay Galeota

JG

Jay Galeota

CEO & President

Therapeutic Areas

Migraine Metabolic Disorders

Kallyope Pipeline

Drug	Indication	Phase
Elismetrep (K-304)	Acute Treatment of Migraine	Phase 2
K-554	Metabolic Disorders / Obesity	Preclinical
Undisclosed Metabolic Program	Metabolic Disorders	Discovery

Leadership Team at Kallyope

Patrick Flanigan

Chief Financial Officer

Brett Lauring, M.D., Ph.D.

Chief Medical Officer

Shirly Pinto, Ph.D.

Chief Scientific Officer

Franz Humer, Ph.D.

Chair, Board of Directors

View full Kallyope profile